The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2025 | Reflecting on the FDA approval of revumenib for KMT2A-rearranged acute leukemia
Florian Perner, MD, Hannover Medical School, Hannover, Germany, reflects on the FDA approval of revumenib for patients with KMT2A-rearranged acute leukemia. He states that this approval marks a significant step for the field as the first menin inhibitor approved, offering hope for patients with highly refractory disease that doesn’t respond well to chemotherapy. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, I mean, I think this approval was a really big step for the field since it was the first menin inhibitor approved in humans. For now, as you said, in KMT2A rearranged leukemia only, so the other entities including NPM1 mutant leukemias are not yet eligible for their treatment. But it’s going to be the first menin inhibitor out and a lot of patients for now, particularly those with highly refractory disease that doesn’t respond or respond well to chemotherapy anymore will benefit from this treatment...
Yeah, I mean, I think this approval was a really big step for the field since it was the first menin inhibitor approved in humans. For now, as you said, in KMT2A rearranged leukemia only, so the other entities including NPM1 mutant leukemias are not yet eligible for their treatment. But it’s going to be the first menin inhibitor out and a lot of patients for now, particularly those with highly refractory disease that doesn’t respond or respond well to chemotherapy anymore will benefit from this treatment. Specifically, elderly patients that receive revuminib as a monotherapy, but also in younger patients as a bridge to transplant I think it will have a very important part in the therapeutic landscape.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
